Cagrilintide amylin laboratory note

Research-use notice: This article is laboratory and educational information only. It is not medical or legal advice, and it does not include how-to-use instructions. BlueNex Labs materials are research use only and are not intended for human or veterinary use. Research-use-only labelling is not a Health Canada authorization.

Publication status: Prepared for the BlueNex Labs Research Knowledge Centre. Literature and library notes checked September 24, 2026. Primary papers and the public COA library can change; verify the lot report in hand before an assay.

Cagrilintide, on this catalogue, is a lyophilized research solid. The shop URL is Cagrilintide 5 mg. This page is the receptor-class note. It is not a sequence card, because the papers checked here do not print a residue string in the text this note relies on. Price and stock stay on the listing.

Receptor class

Kruse and colleagues described development of cagrilintide as a long-acting amylin analogue in the Journal of Medicinal Chemistry in 2021 (PMID 34288673). Fletcher and colleagues, in the Journal of Pharmacology and Experimental Therapeutics in 2021, describe AM833, named there as cagrilintide, as a lipidated amylin analogue and a nonselective agonist at amylin receptors and the calcitonin receptor across the binding and activation endpoints they measured (PMID 33727283). This note cites those two descriptions. It does not copy trial endpoints, and it does not turn a cell assay into a property of the 5 mg cake.

For the glossary line, see amylin analogue. For the class page, see incretin receptor ligands, which keeps amylin, GLP-1, GIP, and glucagon in separate sentences. GLP-1 receptor ligands are a different class. The comparison semaglutide, tirzepatide, and retatrutide and the roundup GLP-1 peptide research in 2026 are neighbours on the metabolic route. They are not cagrilintide. A semaglutide certificate does not document this vial. Retatrutide already has trial and approval notes. This page does not repeat them.

No invented sequence

Lipidation changes the mass relative to unmodified amylin. Without the residue string and the lipid attachment written on the report, a receiver cannot check identity from the product name. Leave the sequence line as "see the lot file." Do not reconstruct a string from a secondary blog. If the PDF names a mass and a species, copy those. If it does not, record the absence. Sequence is linked so the omission is deliberate. Molecular weight is the line the PDF has to supply.

Public trial literature on fixed-dose combinations is not this catalogue lot. An investigational compound is not a Health Canada authorization for a lyophilized solid here. The 5 mg label is a catalogue fill size. It is not a statement about a combination product, and it is not interchangeable with a semaglutide, tirzepatide, or retatrutide milligram size.

Analytical documentation

A catalogue name is not an identity test for Cagrilintide 5 mg. Open how to read a peptide Certificate of Analysis and the purity-versus-mass note. The short version of the same check is the COA verification FAQ. Copy the task identifier from the Janoshik URL on verify.janoshik.com or janoshik.com, the sample name, the date, the mass, the purity figure and its method, and any endotoxin number with its unit. A photograph of a report is not the report. Cap colour and the labelled milligram size are lot-specific. A file for a different size does not document this container.

Chromatographic area percent and mass identity answer different questions. Read chromatogram, mass spectrum, purity versus identity, and molecular weight before you file one number as both answers. Salt form, when the PDF names trifluoroacetate or acetate, is a third line. For the glossary entries, see TFA salt and acetate salt. This catalogue does not publish a house factor that converts a salt weight into a free-base figure. If the report is silent, leave the salt line blank. Net peptide content is recorded only when the PDF states it.

For the library row for a published cagrilintide lot, see Cagrilintide 5 mg in the certificates library. Match the sample name and the 5 mg size. A GLP-1 ligand file does not document an amylin analogue, even when the two vials were ordered together.

The receiving log for this material is ordinary and short. Write the product name, the labelled amount, the cap colour if one is printed, the lot number or batch code, the receipt date, the storage location, the report URL, and whether the sample name matched the container in hand. Quarantine the container when the seal is broken, the solid looks wet, the label does not match the packing list, or the report link will not open. The Burnaby desk can look up an order number. It cannot reconstruct identity from a container that has already been relabelled by hand.

Handling and Canada fulfilment

The solid is stored sealed because residual water can cleave peptide bonds and can collapse a cake. For the format primer, see lyophilized research peptides. Open the parcel the day it arrives. Do not leave it in a vehicle, an outdoor box, or on a loading dock. Move the closed vial into controlled storage and follow the temperature on the product note. A cake that looks different after a cold Canada Post parcel is not an identity test. Do not heat a very cold vial. For the receiving note, see peptide storage for Canadian laboratories. This page does not list a diluent volume. If a laboratory SOP calls for a separate diluent, bacteriostatic water and reconstitution diluent are glossary entries for that reagent, not a volume for this vial.

Paid orders ship on Canada Post Xpresspost inside Canada after Interac e-Transfer. The desk is 4309 Canada Way, Burnaby, BC V5G 1J3. The label sender is a Port Moody, BC PO Box for the carrier account. Put the order number in the Interac message field so the payment can be matched to the emailed invoice. A tracking number is emailed when the label is created. Our parcels are not picked up on weekends or statutory holidays, so a Friday payment can sit until the next operating day. Estimates are not guarantees. Those facts are restated on the shipping FAQ and the payment FAQ. For the procurement note, see Canada laboratory procurement. The shop URL is Cagrilintide 5 mg.

A research-use-only container is not a clinical-trial drug product and it does not carry a Drug Identification Number. The distinction is on the catalogue-versus-trial FAQ. What the research-use-only phrase does and does not do, including the point that the phrase is not by itself a Health Canada authorization, is on the research-use-only FAQ. This page is not legal advice. Domestic Xpresspost keeps the parcel on a Canadian carrier. It does not remove research-use-only limits, and it does not make a catalogue solid into an authorized drug.

Incretin glossary terms, including incretin-receptor ligand and GLP-1 receptor, are linked so a reader can see the boundary. Boundary is the point of the link. The amylin analogue stays on its own anchor.

For the category index that currently lists this material, see the metabolic category. The category lists retatrutide, tirzepatide, and semaglutide beside this vial. Indexing is not identity. Each container keeps its own report.

Frequently asked questions

What receptor class do the cagrilintide papers name?

The 2021 pharmacology paper describes AM833, another name for cagrilintide, as a lipidated amylin analogue and a nonselective agonist at amylin receptors and the calcitonin receptor in the cell assays they ran. The catalogue vial is not those assays.

Why does this note omit a residue string?

The papers checked for this page describe a lipidated amylin analogue. They do not print a residue string in the abstracts used here. The lot report is the identity record. The product name alone does not give the sequence.

Is the 5 mg cagrilintide vial a clinical-trial drug product?

No. It is a lyophilized research solid. Investigational programs and fixed-dose combinations discussed in the literature are not this catalogue lot and are not an approval.

Which comparison page sits next to cagrilintide?

The semaglutide, tirzepatide, and retatrutide comparison. Cagrilintide is an amylin-class analogue, not a GLP-1 substitution series. The pages are neighbours. They are not the same molecule.